A Phase 2 interventional study of Intestinal Low Dose Radiotherapy-1Gy and PD-1/PD-L1 Inhibitors in Metastatic Malignant Solid Neoplasm, Radiotherapy and Immune Checkpoint Blockade, sponsored by Chuangzhen Chen. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Chuangzhen Chen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis — 60 open to participants now, 108 under way, 13 of them phase 3. A drug class: Immune checkpoint inhibitors · Neoplasm Metastasis.
Among the 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis, this one is the 195th largest by enrollment, is one of 20 that started in 2023, is one of 131 in phase 2, and was the 215th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →60 of the 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–75
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75 · Women only
University of California, San Diego · Sites in United States
Ages 18+
NextPoint Therapeutics, Inc. · Sites in United States
Ages 19+
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 101 · Phase 2 163 · Phase 3 25 · Phase 4 3
First in 2004; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 47 across the 262 interventional studies. Of the 122 that completed or were terminated, 59 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 262 have an industry lead sponsor. The 10 most frequent:
Chuangzhen Chen is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Chuangzhen Chen has 1 study filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
30 of the studies testing Immune checkpoint inhibitors in Neoplasm Metastasis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
| NCT04283890Leiden University Medical CenterPHP and Immunotherapy in Metastasized UM | 2026-12 |
| NCT05000710Sheba Medical CenterConcomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy | 2026-12 |
| NCT06787183Fujian Cancer HospitalSCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases | 2026-12-01 |
Add all 30 to your calendar (.ics) → With an account.
Among the 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preclinical and clinical studies have shown that intestinal low dose radiotherapy (ILDR) can enhance antitumor immunity and response to immune checkpoint blockade (ICB). Therefore, the investigators launch a phase Ⅱ trial to evaluate the clinical value of combining ILDR and programmed cell death-1/ -ligand 1 (PD-1/PD-L1) inhibitors in patients with ICB refractory metastatic solid tumor.
This study is designed as a researcher-initiated, two-stage and prospective clinical trial. The target population is patients with advanced metastatic malignant solid tumors who have progressed after immunotherapy. The primary endpoints include objective response rate (ORR), disease control rate (DCR), progression free survival while receiving ILDR combined therapy (PFS2), and lesion-based abscopal response rate. The secondary endpoints include incidence of adverse events (AEs), cancer-specific survival (CSS), and overall response rate (OS).
Sixteen subjects will be enrolled in this trial. The primary objective is to evaluate the safety and efficacy of 1Gy ILDR combined with PD-1/PD-L1 inhibitors in immune-resistant metastatic malignant solid tumors, and biomarker exploration for response prediction.
Eligible patients will be subjected to 1Gy ILDR. Tumor response will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as well as Immune related RECIST (iRECSIST). The extent or severity of adverse reactions will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0). Furthermore, tissue samples, stool samples, and peripheral blood samples will be collected for biomarker exploration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1Gy/1F ILDR + PD-1/PD-L1 inhibitors.
Radiation: Intestinal Low Dose Radiotherapy-1Gy · Drug: PD-1/PD-L1 Inhibitors
1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
Drug page: Immune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
Objective Response Rate (ORR)
The objective effective rate of ILDR combined with PD-1/PD-L1 inhibitors in patients with metastatic malignant solid tumors after acquired resistance to immunotherapy, including complete response and partial response.
Time frame: 6, 12, 24 weeks after start of ILDR.
Disease Control Rate(DCR)
The proportion of patients with optimal response to ILDR combined with PD-1/PD-L1 inhibitors.
Time frame: 6, 12, 24 weeks after start of ILDR.
Progression Free Survival while Receiving ILDR combined Therapy (PFS)
The time from the date of ILDR initiation to the documented disease progression or death due to cancer.
Time frame: 6, 12, 24 weeks after start of ILDR.
Lesion-based Abscopal Response Rate
The proportion of patients with tumor objective response in one or more lesions.
Time frame: 6, 12, 24 weeks after start of ILDR.
Incidence of Adverse Events
The proportion of patients with treatment-related adverse events as assessed by CTCAE v5.0.
Time frame: 12, 24, 48 weeks after start of ILDR.
Overall survival (OS)
The time from the date of ILDR initiation to death from any cause.
Time frame: 24, 48 weeks after start of ILDR.
Cancer-specific survival (CSS)
The time from the date of ILDR initiation to death due to cancer.
Time frame: 24, 48 weeks after start of ILDR.
Changes of Intestinal Flora
Fecal samples are analyzed by metagenomics sequencing. The differential intestinal flora is obtained through differential analysis, and the correlation between the differential microbial communities and other indicators is analyzed.
Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.
Metabolites in fecal samples
The wide arrays of metabolites in fecal samples are analyzed qualitatively and quantitatively.
Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.
Tissue Immune Analyses
Tumor tissue is obtained for histopathological staining and transcriptome sequencing.
Time frame: Before the first treatment, 3 weeks after start of ILDR.
Peripheral Blood Immune Analyses
Flow cytometry analysis is performed on peripheral blood samples.
Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.
Changes of Serum Metabolites
The wide arrays of metabolites in serum are analyzed qualitatively and quantitatively.
Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in May 2026, 28 months.
Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's 28 months is below that.
Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immune checkpoint inhibitors
Chuangzhen Chen